Company Description

FLAG Therapeutics is a near-term clinical stage company focused on developing new small molecule therapeutics for difficult-to-treat cancers. FLAG-003, the company’s lead candidate for the treatment of Diffuse Intrinsic Pontine Glioma (DIPG - a rare and fatal pediatric cancer) and glioblastoma multiform (GBM), is on-track to enter Phase 1 clinical development in early 2026 in children with DIPG.